Towards random sequencing or precision medicine in castration-resistant prostate cancer?

European Urology

Volumn 65, Issue 1, 2014, Pages 37-38

  Loriot, Yohann ^a   Fizazi, Karim ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROSTANOLONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RAPAMYCIN; SIPULEUCEL T; TESTOSTERONE; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ANTINEOPLASTIC ACTIVITY; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CROSS RESISTANCE; DEATH; EDITORIAL; EXOME; HUMAN; MALE; METABOLOMICS; MUTATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TRANSACTIVATION; TRANSCRIPTOMICS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; ANALOGS AND DERIVATIVES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84888833649     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.09.019     Document Type: Editorial

References (16)

1. C. Massard, and K. Fizazi Targeting continued androgen receptor signaling in prostate cancer Clin Cancer Res 17 2011 3876 3883
2. K. Fizazi, H.I. Scher, A. Molina COU-AA-301 Investigators Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
3. H.I. Scher, K. Fizazi, F. Saad AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
4. J.S. de Bono, S. Oudard, M. Ozguroglu TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
5. C. Parker, S. Nilsson, D. Heinrich ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
6. C.J. Ryan, M.R. Smith, J.S. de Bono COU-AA-302 Investigators Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
7. P.W. Kantoff, C.S. Higano, N.D. Shore IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
8. A.J. Schrader, M. Boegemann, and C.-H. Ohlmann Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
9. Y. Loriot, D. Bianchini, and E. Ileana Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
10. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
11. E.A. Mostaghel, B.T. Marck, and S.R. Plymate Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
12. R. Hu, C. Lu, and E.A. Mostaghel Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 72 2012 3457 3462
13. E. Efstathiou, M.A. Titus, and D. Tsavachidou MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report [abstract] J Clin Oncol 29 Suppl 15 2011 289s
14. C. Cai, S. Chen, and P. Ng Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
15. E. Efstathiou, M. Titus, and D. Tsavachidou Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637 643
16. C.S. Grasso, Y.M. Wu, and D.R. Robinson The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243